Literature DB >> 16817842

Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study.

Gang Chen1, Wenyao Lin, Fumin Shen, Uchenna H Iloeje, W Thomas London, Alison A Evans.   

Abstract

BACKGROUND AND AIMS: In a prospective cohort study with 11 yr of follow-up, we assessed the relationship between past hepatitis B virus (HBV) viral load and mortality. Surviving cohort members were evaluated for current liver disease.
METHODS: We measured HBV viral load by real-time polymerase chain reaction on stored samples from cohort entry (1992-1993) in 2,763 hepatitis B surface antigen (HBsAg)-positive adults. Major end points were death from hepatocellular carcinoma (HCC) or chronic liver disease (CLD). There were 447 deaths. In the 1,683 survivors, we assessed severity of liver disease on a return visit in 2003. Viral load was divided into three categories: undetected (<1.6 x 10(3) copies/mL); low titer (<10(5) copies/mL); and high titer (> or =10(5) copies/mL).
RESULTS: For HCC, there was a significant increase in mortality across viral load categories (p(trend) < 0.001). Compared to the HBV undetected category, the relative risk (RR) for HCC mortality in the low viral load group was 1.7 (95% confidence interval [CI] 0.5-5.7) and 11.2 (3.6-35.0) in the high viral load group. For CLD mortality, the RRs were 1.5 (0.2-12.1) and 15.2 (2.1-109.8), respectively (p(trend) < 0.001). The RR associated with high viral load did not change with increased follow-up time. In surviving cohort members evaluated for liver disease in 2003, there was also a significant association of viral load with disease severity.
CONCLUSION: In this prospective study, viral load is associated with increased mortality from HCC and CLD in HBV-infected subjects. Viral load may be a useful prognostic tool in HBV infection, and interventions aimed at its reduction should be explored.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817842     DOI: 10.1111/j.1572-0241.2006.00647.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  67 in total

1.  Canadian patients with chronic hepatitis B cannot access appropriate drug treatments: a call for change.

Authors:  Morris Sherman; Samuel S Lee
Journal:  Can J Gastroenterol       Date:  2011-10       Impact factor: 3.522

Review 2.  Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis.

Authors:  Asmaa-Ibrahim Gomaa; Shahid-A Khan; Mireille-B Toledano; Imam Waked; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-07-21       Impact factor: 5.742

3.  In vitro anti-hepatitis B virus effect of Hypericum perforatum L.

Authors:  Ran Pang; Junyan Tao; Shuling Zhang; Jiang Zhu; Xin Yue; Lei Zhao; Pian Ye; Ying Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-02-14

4.  Management of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelines.

Authors:  Carla S Coffin; Scott K Fung; Mang M Ma
Journal:  Can J Gastroenterol       Date:  2012-12       Impact factor: 3.522

5.  [4. Austrian consensus-statement for diagnosis and therapy of hepatitis B 2009].

Authors:  Markus Peck-Radosavljevic; Johann Deutsch; Peter Ferenci; Ivo Graziadei; Harald Hofer; Heidemarie Holzmann; Wolf-Dietrich Huber; Herman Laferl; Andreas Maieron; Rudolf Stauber; Wolfgang Vogel
Journal:  Wien Klin Wochenschr       Date:  2010-05-04       Impact factor: 1.704

Review 6.  Individualized hepatocellular carcinoma risk: the challenges for designing successful chemoprevention strategies.

Authors:  Cristina Della Corte; Alessio Aghemo; Massimo Colombo
Journal:  World J Gastroenterol       Date:  2013-03-07       Impact factor: 5.742

7.  Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.

Authors:  Sang Hoon Ahn; Henry L Y Chan; Pei-Jer Chen; Jun Cheng; Mahesh K Goenka; Jinlin Hou; Seng Gee Lim; Masao Omata; Teerha Piratvisuth; Qing Xie; Hyung Joon Yim; Man-Fung Yuen
Journal:  Hepatol Int       Date:  2010-02-20       Impact factor: 6.047

8.  High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.

Authors:  Jie Hu; Yang Xu; Zao-Zhuo Shen; Zheng Wang; Qing Lu; Guo-Huan Yang; Zheng-Bin Ding; Jia Fan; Jian Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-07       Impact factor: 4.553

9.  Hepatitis B viral load and risk for liver cirrhosis and hepatocellular carcinoma in The Gambia, West Africa.

Authors:  M E Mendy; T Welzel; O A Lesi; P Hainaut; A J Hall; M H Kuniholm; S McConkey; J J Goedert; S Kaye; S Rowland-Jones; H Whittle; G D Kirk
Journal:  J Viral Hepat       Date:  2009-10-27       Impact factor: 3.728

10.  Hepatitis B virus pre-S deletion mutations are a risk factor for hepatocellular carcinoma: a matched nested case-control study.

Authors:  Zhong-Liao Fang; Caroline A Sabin; Bai-Qing Dong; Shao-Chao Wei; Qin-Yan Chen; Kong-Xiong Fang; Jin-Ye Yang; Jian Huang; Xue-Yan Wang; Tim J Harrison
Journal:  J Gen Virol       Date:  2008-11       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.